Ikena Oncology (Ikena Oncology) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ikena Oncology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ikena Oncology's Free Cash Flow for the three months ended in Mar. 2024 was $-18.30 Mil. Ikena Oncology's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Ikena Oncology's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Ikena Oncology's current FCF Yield % is -121.94%.

The historical rank and industry rank for Ikena Oncology's FCF Margin % or its related term are showing as below:

IKNA' s FCF Margin % Range Over the Past 10 Years
Min: -2033.86 Med: -419.75 Max: 346.19
Current: -2033.86

During the past 5 years, the highest FCF Margin % of Ikena Oncology was 346.19%. The lowest was -2033.86%. And the median was -419.75%.

IKNA's FCF Margin % is ranked worse than
82.11% of 1045 companies
in the Biotechnology industry
Industry Median: -143.92 vs IKNA: -2033.86

Ikena Oncology FCF Margin % Historical Data

The historical data trend for Ikena Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ikena Oncology FCF Margin % Chart

Ikena Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

346.19

-419.75

-200.14

-483.67

-875.08

Ikena Oncology Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial													-375.23	-905.34	-1,687.51	-3,310.93	-

Competitive Comparison of Ikena Oncology's FCF Margin %

For the Biotechnology subindustry, Ikena Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ikena Oncology's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ikena Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Ikena Oncology's FCF Margin % falls into.

Ikena Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Ikena Oncology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-80.157	/	9.16
	=	-875.08 %

Ikena Oncology's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-18.304	/	0
	=	%

Ikena Oncology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Ikena Oncology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ikena Oncology (Ikena Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ikena Oncology Inc (NAS:IKNA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Suite 101, Boston, MA, USA, 02210

Website

https://www.ikenaoncology.com

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.

Executives

Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Jotin Marango	officer: CFO & Head of Corp. Dev.	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Francisco Oliveira	officer: Principal Accounting Officer	IKENA ONCOLOGY, INC., 645 SUMMER STREET, SUITE 101, BOSTON MA 02210
Richard Wooster	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Xiaoyan Michelle Zhang	officer: Chief Scientific Officer	C/O IKENA ONCOLOGY, INC., 645 SUMMER STREET SUITE 101, BOSTON MA 02210
Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Maria Koehler	director	C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Mark Manfredi	director, officer: President & CEO	C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Maude Tessier	officer: Chief Business Officer	C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey Ecsedy	officer: Chief Scientific Officer	C/O IKENA ONCOLOGY, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Atlas Venture Associates Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, Llc	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139